Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2431MR)

This product GTTS-WQ2431MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2431MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12186MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ8138MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ15557MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1639MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ2606MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ868MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ7558MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ14396MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW